CG Oncology

CGON

Market cap $4.52B

CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites.

CG Oncology maintains a "Strong Buy" rating, driven by significant pipeline progress and multiple upcoming catalysts in 2026. Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Early enrollment completion in the phase 3 PIVOT-006 trial for IR-NMIBC accelerates topline data to 1H 2026, positioning the company for a potential first FDA approval in this segment.

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule

IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.

CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities.

IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which demonstrated promising efficacy, safety and tolerability. These data will be presented today as Late-Breaking Abstracts at the Society of Urologic Oncology (SUO) 26th Annual Meeting.

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors.

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago.

IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2025, and provided business updates.